| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| Other Sizes |
| Targets |
Target: Isotope-Labeled Compounds / Endogenous Metabolite. Stearic acid is a long-chain dietary saturated fatty acid found in many animal and vegetable fats and oils; it functions as an energy source and structural component of cell membranes.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, stearic acid-d7 is a standard reference for quantitative analysis and quality control. It is used in cell culture studies as a tracer to monitor fatty acid uptake, beta-oxidation, and incorporation into complex lipids, without exerting direct pharmacological activity. |
| ln Vivo |
In vivo, the compound is used in metabolic flux studies and tracer experiments to track dietary C18:0 metabolism, desaturation to C18:1, and beta-oxidation to C16:0 over time, after oral or intravenous administration to rodents. It does not exert pharmacological activity.
|
| Enzyme Assay |
For cell-free assays: plasma, tissue homogenates, or cell lysates are processed by lipid extraction (Folch method) followed by saponification and derivatization to fatty acid methyl esters (FAMEs). The samples are analyzed by GC-MS or LC-MS, and the labeled internal standard enables absolute quantitation of stearic acid.
|
| Cell Assay |
For cell assays: myotubes, hepatocytes, or adipocytes are incubated with media containing stearic acid-d7 (typically 10-100 uM) complexed to bovine serum albumin for 2-24 hours. Fatty acid oxidation is assessed by measuring 13C or 2H incorporation into CO2, or by lipid extraction for labeled TG and CE analysis by MS.
|
| Animal Protocol |
For animal studies: mice are administered stearic acid-d7 (oral gavage or IV bolus, typically 10-50 mg/kg) for metabolic tracer studies. Serial blood samples are collected, and tissues are harvested post-mortem for analysis of incorporated label into various lipid classes by LC-MS.
|
| ADME/Pharmacokinetics |
PK properties are consistent with natural stearic acid: rapid plasma clearance, extensive uptake by the liver and adipose tissue, and a metabolic half-life measured in minutes to hours depending on oxidation rate. The deuterated standard does not alter the PK profile.
|
| Toxicity/Toxicokinetics |
No toxicity is associated with this compound at tracer or internal standard levels. Stearic acid itself can be cytotoxic at supraphysiological concentrations (≥500 uM) in some cell types via ER stress and apoptosis, but these effects are not observed with standard tracer use.
|
| References | |
| Additional Infomation |
Stearic acid-d7 is a research standard, not a drug. It is not intended for human therapeutic use. It is used extensively in metabolic research to study inborn errors of fatty acid oxidation, insulin resistance, and lipid metabolism in obesity, diabetes, and cardiovascular disease.
|
| Molecular Formula |
C18H36O2
|
|---|---|
| Molecular Weight |
291.520378112793
|
| Exact Mass |
284.272
|
| CAS # |
951209-59-9
|
| Related CAS # |
Stearic acid;57-11-4
|
| PubChem CID |
118796525
|
| Appearance |
White to off-white solid powder
|
| LogP |
6.332
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
20
|
| Complexity |
202
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])C([2H])([2H])C([2H])([2H])CCCCCCCCCCCCCCC(=O)O
|
| InChi Key |
QIQXTHQIDYTFRH-NCKGIQLSSA-N
|
| InChi Code |
InChI=1S/C18H36O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h2-17H2,1H3,(H,19,20)/i1D3,2D2,3D2
|
| Chemical Name |
16,16,17,17,18,18,18-heptadeuteriooctadecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4303 mL | 17.1515 mL | 34.3030 mL | |
| 5 mM | 0.6861 mL | 3.4303 mL | 6.8606 mL | |
| 10 mM | 0.3430 mL | 1.7151 mL | 3.4303 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
